1236002-97-3

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 99-09-2 3-nitro-aniline 

Downstream Products

• 1236003-01-2 N₄-(3-nitrophenyl)-N₂-(pyrazin-2-yl)pyrimidine-2,4-diamine 
• 1236003-04-5 N₂-(6-methoxypyridin-3-yl)-N₄-(3-nitrophenyl)pyrimidine-2,4-diamine 
• 1236003-07-8 N₂-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-N₄-(3-nitrophenyl)pyrimidine-2,4-diamine 
• 1236003-10-3 N₂-(1-benzyl-1H-benzo[d]imidazol-2-yl)-N₄-(3-nitrophenyl)pyrimidine-2,4-diamine 

Relevant academic research and scientific papers

KINASE INHIBITORS FOR THE TREATMENT OF DISEASE

The invention relates to compounds and their use in the treatment of disease. Novel irreversible inhibitors of wild-type and mutant forms of EGFR, FGFR, ALK, ROS, JAK, BTK, BLK, ITK, TEC, and/or TXK and their use for the treatment of cell proliferation disorders are described.

KINASE INHIBITORS

Provided herein are kinase inhibiting compounds and methods of using the same.

Convenient preparation of 4-aryl-2-(heteroarylamino)pyrimidines and 4-anilino-2-(heteroarylamino)pyrimidines

4-Aryl-2-anilinopyrimidines and 2,4-dianilinopyrimidines are privileged structures found in many drug-like molecules and biologically active compounds. A method for the quick assembly of novel 4-aryl- and 4-anilino-2-(heteroarylamino)pyrimidines via Buchwald-Hartwig N-arylations at elevated temperatures under sealed tube conditions is reported. This method's convenience and practicality is demonstrated through the preparation of several novel non-nucleoside reverse transcriptase inhibitor (NNRTI) analogues.